Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Myriad Genetics's total debt was $120.70M at Jun 30, 2026. For fiscal 2025 it was $119.90M, up 202.8% from the year before. The highest annual figure on record is $233.50M in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.90M | +202.8% |
| FY2024 | Dec 31, 2024 | $39.60M | +2.9% |
| FY2023 | Dec 31, 2023 | $38.50M | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2020 | Jun 30, 2020 | $224.40M | -3.9% |
| FY2019 | Jun 30, 2019 | $233.50M | +2410.8% |
| FY2018 | Jun 30, 2018 | $9.30M | -90.6% |
| FY2017 | Jun 30, 2017 | $99.10M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $120.70M | +103.2% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $120.30M | +102.9% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $119.90M | +202.8% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $119.50M | +206.4% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $59.40M | +53.1% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $59.30M | +53.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $39.60M | +2.9% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $39.00M | +1.3% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $38.80M | +1.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $38.70M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $38.50M | -82.8% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $38.50M | -82.9% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $38.40M | -82.9% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $0 | -100.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $224.40M | -3.9% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $225.20M | -14.5% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $225.10M | -17.6% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $225.00M | -12.8% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $233.50M | +2410.8% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $263.40M | +280.1% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $273.30M | +532.6% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $258.00M | +160.3% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $9.30M | -95.3% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $69.30M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $43.20M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $99.10M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $199.20M | – |
See a number that looks wrong?